Neuro-Biotech Pursues the Implementation of its Licensees Network and Signs a LOI with Israel
BASEL, Switzerland, Jan. 25, 2011 - CNW TELBEC - Neuro-Biotech Corp. ( MRES-OTцQB) is pleased to announce the signing of a Letter of Intent with a major distributor in Israel. Both groups are discussing the details of a Licensing Agreement based on similar terms and conditions as the recently negotiated agreement with the Russian company Credo-TM.
Credo-TM has strong relationship with Israel pharmaceutical business and actively participates in negotiation process.
Furthermore, Neuro-Biotech intends to contract the manufacturing of the tests ordered by its Licensee in Israel and to that effect discussions have already taken place with one of the biggest pharmaceutical firm in Israel.
With the signing of this Letter of Intent with the Israelis, Neuro-Biotech gains a strong foothold and is able to pursue in an accelerated way the implementation of its Licensee network throughout the world. This allows the Company to initiate the next phase of its development plan namely the creation of its own "Technological Showcase" to support the training of technicians and the development of new products.
For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company`s actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company`s actual results to differ materially from those indicated in any forward-looking statements.
|
